Global Implantable Drug Delivery Market is expected to reach US$ 36.12 bn by 2026 at a CAGR of 8.5 % during the forecast period.
The Implantable Drug Delivery market is segmented based on product type, technology, application, and region. based on Product type – Implantable bio-absorbable stents, implantable contraceptive drug delivery devices, implantable intraocular drug delivery devices, implantable coronary drug-eluting stents, implantable brachytherapy seeds, an implantable drug infusion pumps.By Technology – Biodegradable implantable drug delivery device technology and non-biodegradable implantable drug delivery device technology.
By application – cardiovascular, birth control & contraception, ophthalmology, oncology, and others. Implantable drug delivery devices are medical devices that allow site-specific drug management. It also offers the minimization of the doses of the drug for the reduction of potential side effects. The implantable devices are reaching more attention as compared to the conservative oral and parenteral dosage forms because of the site-specific and sustained release therapeutic action, implantable devices that again minimizes the side-effects associated with the drug.
Cardiovascular applications hold the dominant share in forecast period due to increasing patient population suffering from cardiovascular diseases, which drives the clinical urgency to develop advanced devices. As a result, global key players have developed bioabsorbable stents that are gradually immersed and excreted by the body.
Bioabsorbable stents are expected to reveal exponential CAGR throughout the forecast period due to the growing incidence of peripheral and coronary artery diseases, increasing patient-controlled devices, shifting effort of manufactures on clinical trials related to bioresorbable stents, growing adoption by patients and physicians, and rising demand for minimally invasive surgeries.
The North American region is playing the principal role in the implantable drug delivery market due to rising demand for minimally invasive surgeries, their income levels in developed economies, technology advancements in implantable drug deliveries. Though, Asia-Pacific will be the second major market in the proximate future followed by LAMEA region. The presence of innovative medical advanced technology and increasing demand for contraceptive implants in the coming years.
key players operated in the market are Bayer, Boston Scientific, Medtronic, Merck&Co. Inc., Allergan Inc., Bausch and Lomb, Inc., Ithetis, Nucletron, Genetech Inc., Theragenics, Psivida, Kinamed Inc., K2M Inc., Mako Surgical Corp., Varian Medical System, Arrow International, Eckert Ziegler, Elekta, JVS, Abbottamong among others.
Scope of Global Implantable Drug Delivery Market:
Global Implantable Drug Delivery Market, Product Type:
- Implantable Bio-Absorbable Stents
- Implantable Contraceptive Drug Delivery Devices
- Implantable Intraocular Drug Delivery Devices
- Implantable Coronary Drug Eluting Stents
- Implantable Brachytherapy Seeds
- Implantable Drug Infusion Pumps
Global Implantable Drug Delivery Market, by Technology:
- Biodegradable implantable drug delivery device technology
- Non-biodegradable implantable drug delivery device technology.
Global Implantable Drug Delivery Market, by Application:
- Cardiovascular
- Birth control & contraception
- Ophthalmology
- Oncology
- Others.
Global Implantable Drug Delivery Market, By Region:
- North America
- Europe
- Asia pacific
- Middle East & Africa
- Latin America
Global Implantable Drug Delivery Market Key Players:
- Bayer
- Boston Scientific
- Medtronic
- Merck&Co. Inc.
- Allergan Inc.
- Bausch and Lomb, Inc.
- Ithetis
- Nucletron, Genetech Inc.
- Theragenics
- Psivida
- Kinamed Inc.
- K2M Inc.
- Mako Surgical Corp.
- Varian Medical System
- Arrow International
- Eckert Ziegler
- Elekta
- JVS
- Abbottamong among others.
